史礼帅 医师
整形外科医师, (Resident)
其他作者: Rizwan Ali, Traidit THIANTHANYAKIJ, Shanshan Qiu, Haiyan Cui
Current Status and Perception of Biostimulators in China: A Cross-Sectional Study on Medical Professionals and Patients
Objectives: To assess the current application and perceptions of biostimulators among medical professionals and patients in China, providing data to guide clinical practice.
Introduction: Aging embodies humanity’s profound sorrow, while beauty remains an eternal pursuit. ISAPS data reports 34.9 million aesthetic procedures in 2023, with non-surgical treatments growing 5.5% faster than surgical ones. Biostimulators, stimulating extracellular matrix regeneration, are emerging as alternatives to collagen/hyaluronic acid fillers, yet lack extensive clinical data in China since the first biostimulator was approved in 2021. Injectable practitioners require deeper material insights to optimize safe, effective applications.
Materials / method: A cross-sectional study employing convenience sampling was conducted. Questionnaires were distributed to aesthetic medical professionals and patients with biostimulator experience. Physician and Patient surveys were collected offline between November 2024. Descriptive statistics were analyzed using SPSS 22.0, with absolute numbers and percentages (%) reported. The ranking questions were analyzed using the reverse scoring method.
Results: Biostimulators were widely applied for natural aesthetic outcomes (physicians: 84.0%; patients: 67.67%), particularly in facial treatments. Gender-specific preferences were observed, with males prioritizing contour definition and females favoring tightness and lifting. However, 40.0% of physicians expressed dissatisfaction with product longevity, while 39.2% desired enhanced efficacy. Additionally, 19.2%, 43.2%, and 14.4% of physicians reported dissatisfaction with pre-mixing protocols, storage stability, and post-injection massage techniques, respectively.
Conclusion: Biostimulators are increasingly utilized for their natural aesthetic outcomes, though safety remains the primary concern. Comprehensive preclinical data and reliable clinical evidence are critical for product selection. We advocate for collaborative efforts among manufacturers, frontline clinicians, and basic research professionals to develop detailed clinical guidelines and standardized training programs, thereby improving satisfaction among healthcare providers and patients alike.